Quarterly report · Q1
8129.TEDINET S100OXRX
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥323.4bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥1.27T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥308.8bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥1.4bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥635m | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.3bn | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.0bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.4bn | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.7bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥1.7bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥710.1bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥702.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥697.5bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥466.3bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥461.1bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥243.7bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥241.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥237.4bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥94.4bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥94.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥29.22 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥189.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.55 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥26.86 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥174.48 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.55 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 34.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.0% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥14.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥14.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥401m |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥22.2bn |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥22.2bn |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥133m |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.5bn |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥612m |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥288m |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥311.8bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥299.4bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥12.4bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥356m |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥94m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥338.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥323.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥14.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥14.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥14.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥466m |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥22.5bn |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥22.5bn |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥0 |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥350m |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥403m |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥1.5bn |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥195m |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥297.6bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥284.9bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥12.7bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥554m |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥966m |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥305m |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥0 |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥323.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥308.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥14.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | ¥1.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 420
| Item | Context | Value | Unit |
|---|---|---|---|
| Short term loans payable | Prior1YearInstant | 6545000000 | JPY |
| Short term loans payable | CurrentQuarterInstant | 6499000000 | JPY |
| Current portion of bonds | Prior1YearInstant | - | JPY |
| Current portion of bonds | CurrentQuarterInstant | 20018000000 | JPY |
| Income taxes payable | Prior1YearInstant | 5416000000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 1644000000 | JPY |
| Provision for bonuses | Prior1YearInstant | 3252000000 | JPY |
| Provision for bonuses | CurrentQuarterInstant | 4925000000 | JPY |
| Provision for directors bonuses | Prior1YearInstant | 53000000 | JPY |
| Provision for directors bonuses | CurrentQuarterInstant | 10000000 | JPY |
| Asset retirement obligations cl | Prior1YearInstant | 4000000 | JPY |
| Asset retirement obligations cl | CurrentQuarterInstant | 6000000 | JPY |
| Other cl | Prior1YearInstant | 17535000000 | JPY |
| Other cl | CurrentQuarterInstant | 18295000000 | JPY |
| Current liabilities | Prior1YearInstant | 402819000000 | JPY |
| Current liabilities | CurrentQuarterInstant | 428430000000 | JPY |
| Bonds payable | Prior1YearInstant | 20023000000 | JPY |
| Bonds payable | CurrentQuarterInstant | - | JPY |
| Long term loans payable | Prior1YearInstant | 12596000000 | JPY |
| Long term loans payable | CurrentQuarterInstant | 11969000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 2423000000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 2419000000 | JPY |
| Asset retirement obligations ncl | Prior1YearInstant | 2741000000 | JPY |
| Asset retirement obligations ncl | CurrentQuarterInstant | 2747000000 | JPY |
| Provision for loss on anti monopoly act ncl | Prior1YearInstant | 3639000000 | JPY |
| Provision for loss on anti monopoly act ncl | CurrentQuarterInstant | 3639000000 | JPY |
| Other ncl | Prior1YearInstant | 16850000000 | JPY |
| Other ncl | CurrentQuarterInstant | 17109000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 58275000000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 37884000000 | JPY |
| Liabilities | Prior1YearInstant | 461095000000 | JPY |
| Liabilities | CurrentQuarterInstant | 466314000000 | JPY |
| Capital stock | Prior1YearInstant | 10649000000 | JPY |
| Capital stock | CurrentQuarterInstant | 10649000000 | JPY |
| Capital surplus | Prior1YearInstant | 49228000000 | JPY |
| Capital surplus | CurrentQuarterInstant | 49228000000 | JPY |
| Retained earnings | Prior1YearInstant | 180254000000 | JPY |
| Retained earnings | CurrentQuarterInstant | 181229000000 | JPY |
| Treasury stock | Prior1YearInstant | -15719000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -15719000000 | JPY |
| Shareholders equity | Prior1YearInstant | 224413000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 225388000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 20792000000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 22271000000 | JPY |
| Revaluation reserve for land | Prior1YearInstant | -4273000000 | JPY |
| Revaluation reserve for land | CurrentQuarterInstant | -4273000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 16518000000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | 17997000000 | JPY |
| Subscription rights to shares | Prior1YearInstant | 149000000 | JPY |
| Subscription rights to shares | CurrentQuarterInstant | 149000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |